The two patients with secondary cutaneous involvement of systemic DLBCL, both BCL6+, showed either strong (n = 1) or weak (n = 1) TOX expression in more than 75 % of the neoplastic B-cells. The gene discussed is TOX; the disease is diffuse large B-cell lymphoma.